Migraine Stocks List

Migraine Stocks Recent News

Date Stock Title
Nov 22 ABBV AbbVie gains on Leerink Partners upgrade to Outperform
Nov 22 ABBV AbbVie: Upgrading To 'Strong Buy' After Pullback
Nov 22 ABBV J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis
Nov 22 ABBV AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
Nov 22 ABBV AbbVie upgraded to outperform by Leerink on recent sell-off
Nov 21 AMRX Amneal gets FDA approval for generic Byetta, resubmits DHE NDA
Nov 21 AMRX Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
Nov 20 ABBV Unpacking the Latest Options Trading Trends in AbbVie
Nov 19 RVNC Revance Therapeutics gains as Crown Labs further extends tender offer
Nov 19 ABBV Where Will AbbVie Be in 5 Years?
Nov 19 ABBV ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
Nov 19 ABBV RVPH: Year-End OLE Update
Nov 19 ABBV What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
Nov 18 ABBV AbbVie snaps eight straight sessions of losses
Nov 18 ABBV Aldeyra announces FDA acceptance of resubmitted reproxalap application
Nov 18 ABBV AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
Nov 18 ABBV Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
Nov 18 ABBV AbbVie’s Elahere wins European approval for certain ovarian cancers
Nov 18 ABBV Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Nov 18 ABBV AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
Migraine

A migraine is a primary headache disorder characterized by recurrent headaches that are moderate to severe. Typically, the headaches affect one half of the head, are pulsating in nature, and last from two to 72 hours. Associated symptoms may include nausea, vomiting, and sensitivity to light, sound, or smell. The pain is generally made worse by physical activity. Up to one-third of people have an aura: typically a short period of visual disturbance that signals that the headache will soon occur. Occasionally, an aura can occur with little or no headache following it.Migraines are believed to be due to a mixture of environmental and genetic factors. About two-thirds of cases run in families. Changing hormone levels may also play a role, as migraines affect slightly more boys than girls before puberty and two to three times more women than men. The risk of migraines usually decreases during pregnancy. The underlying mechanisms are not fully known. They are, however, believed to involve the nerves and blood vessels of the brain.Initial recommended treatment is with simple pain medication such as ibuprofen and paracetamol (acetaminophen) for the headache, medication for the nausea, and the avoidance of triggers. Specific medications such as triptans or ergotamines may be used in those for whom simple pain medications are not effective. Caffeine may be added to the above. A number of medications are useful to prevent attacks including metoprolol, valproate, and topiramate.Globally, approximately 15% of people are affected by migraines. It most often starts at puberty and is worst during middle age. In some women they become less common following menopause. As of 2016 it is one of the most common causes of disability. An early description consistent with migraines is contained in the Ebers papyrus, written around 1500 BCE in ancient Egypt. The word "migraine" is from the Greek ἡμικρανία (hemikrania), "pain on one side of the head", from ἡμι- (hemi-), "half", and κρανίον (kranion), "skull".

Browse All Tags